| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Magnoloside B primarily targets α-glucosidase, an enzyme responsible for the hydrolysis of carbohydrate glycosidic bonds in the intestinal brush border. By inhibiting α-glucosidase activity, the compound slows carbohydrate digestion and glucose absorption, which may contribute to hypoglycemic effects. Additionally, Magnoloside B has been shown to exhibit moderate inhibitory activity against cancer cells, suggesting potential involvement in pathways related to cell proliferation and survival. Its antioxidant properties may also contribute to its biological activities by reducing oxidative stress.
|
|---|---|
| ln Vitro |
In cell-free biochemical assays, Magnoloside B inhibits α-glucosidase with an IC50 of 0.69 mM. In cellular studies, the compound demonstrates moderate inhibitory activity against MGC-803 (gastric cancer) and HepG2 (hepatocellular carcinoma) cell lines. These anticancer activities are moderate in potency, indicating that Magnoloside B may serve as a lead compound for further optimization rather than a highly potent therapeutic agent. The compound also shows protective effects against free radical-induced oxidative damage in cell-based models.
|
| ln Vivo |
Specific in vivo data for Magnoloside B are limited in the available literature. However, given its α-glucosidase inhibitory activity, the compound is expected to have potential for studying glycemic control in animal models of diabetes. In vivo studies would typically involve oral administration of the compound to diabetic or high-fat diet-induced obese rodents, followed by measurements of blood glucose levels, oral glucose tolerance tests, and assessments of insulin sensitivity. The compound's antioxidant properties may also be evaluated in models of oxidative stress-related diseases.
|
| Enzyme Assay |
The α-glucosidase inhibitory activity is assessed using a colorimetric enzyme assay. α-Glucosidase enzyme (from Saccharomyces cerevisiae or rat intestinal acetone powder) is incubated with various concentrations of Magnoloside B and the substrate p-nitrophenyl-α-D-glucopyranoside (pNPG). The reaction is carried out at 37°C for a defined period, and the amount of p-nitrophenol released is measured spectrophotometrically at 405 nm. IC50 values are calculated from dose-response curves by nonlinear regression analysis.
|
| Cell Assay |
Cellular activity is evaluated using MGC-803 (gastric cancer) and HepG2 (hepatocellular carcinoma) cell lines. Cells are cultured in appropriate media supplemented with 10% FBS at 37°C in 5% CO₂. Magnoloside B is added at various concentrations for 24-72 hours, and cell viability is assessed using MTT, CCK-8, or CellTiter-Glo assays. The IC50 for cell growth inhibition is determined from dose-response curves. Additionally, antioxidant activity can be assessed in cells exposed to oxidative stress inducers such as H₂O₂, with cell viability and ROS levels measured as endpoints.
|
| Animal Protocol |
In vivo studies for Magnoloside B would be conducted in appropriate animal models depending on the research focus. For diabetes research, the compound would be administered orally to diabetic mice or rats (e.g., streptozotocin-induced or db/db mice), and blood glucose levels would be monitored over time. For cancer research, xenograft models using MGC-803 or HepG2 cells could be employed. However, specific in vivo protocols for Magnoloside B have not been reported in the literature, and studies would follow standard protocols for the respective disease models.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Magnoloside B are not available in the current literature. As a glycoside with a molecular weight of 786.73 g/mol, the compound is expected to have low oral bioavailability due to poor membrane permeability and potential first-pass metabolism. Glycosides are typically hydrolyzed by intestinal β-glucosidases before absorption, which may limit their systemic exposure. Pharmacokinetic studies would be required to determine the compound's absorption, distribution, metabolism, and excretion profile in animal models.
|
| Toxicity/Toxicokinetics |
Toxicological data for Magnoloside B are limited. As a natural product isolated from Magnolia officinalis, which has a history of use in traditional medicine, the compound is generally considered to have a moderate safety profile at the concentrations used in research. However, systematic toxicology studies including acute toxicity, repeated-dose toxicity, and genotoxicity assessments have not been reported. As with any research compound, appropriate safety precautions should be taken when handling, and the compound should be used only in controlled laboratory settings.
|
| References | |
| Additional Infomation |
Magnologin B is an oligosaccharide. It has been reported that magnologin B exists in Magnolia ovata, and relevant data are available for reference.
Magnoloside B is a naturally occurring phenylethanol glycoside from Magnolia officinalis with α-glucosidase inhibitory activity (IC50 = 0.69 mM). It shows moderate anticancer activity against MGC-803 and HepG2 cells and has protective effects against oxidative damage. The compound has potential applications in diabetes and cancer research. No clinical trials or regulatory approvals have been reported for Magnoloside B. It is exclusively a research compound for in vitro and preclinical studies. All information is based on published literature and supplier data. |
| Molecular Formula |
C35H46O20
|
|---|---|
| Molecular Weight |
624.58714
|
| Exact Mass |
786.258
|
| CAS # |
116872-05-0
|
| PubChem CID |
14018784
|
| Appearance |
Light yellow to yellow solid
|
| Source |
Originated from plants: Magnoliaceae Magnolia officinalis. Rehd. et Wils.
|
| LogP |
-2.1
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
55
|
| Complexity |
1230
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(OC[C@@H]1O[C@@H](OCCC2=CC=C(O)C(O)=C2)[C@@H](O)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)[C@H]1O)/C=C/C1=CC=C(O)C(O)=C1
|
| InChi Key |
MGCIVWNKCIWQHX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C35H46O20/c1-14-24(42)27(45)30(48)34(51-14)55-32-31(54-23(41)7-4-15-2-5-17(37)19(39)10-15)26(44)22(13-50-33-29(47)28(46)25(43)21(12-36)52-33)53-35(32)49-9-8-16-3-6-18(38)20(40)11-16/h2-7,10-11,14,21-22,24-40,42-48H,8-9,12-13H2,1H3
|
| Chemical Name |
[2-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-4-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~127.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6011 mL | 8.0053 mL | 16.0105 mL | |
| 5 mM | 0.3202 mL | 1.6011 mL | 3.2021 mL | |
| 10 mM | 0.1601 mL | 0.8005 mL | 1.6011 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
